Chimerix’s lead clinical pipeline candidate is dordaviprone, a first-in-class small molecule treatment designed to selectively target the mitochondrial protease ClpP and dopamine receptor D2 (DRD2).

Experiments in rats suggest that reduced dopamine receptor availability in the ... Rats selected in this way also had reduced levels of available DRD2 in ventral striata, as detected by ...

Dopamine receptors are a primary target of the SGAs, and many studies have tested whether variation in the dopamine receptor genes correlate with treatment response and/or side effect profiles.